Genotype-guided antiplatelet therapy for stroke patients
Part of Brain & nervous system, Heart & circulation clinical trials.
This trial tests whether using a rapid genetic test to choose antiplatelet medication can improve outcomes for people who have had a stroke or mini-stroke. The test checks a gene that affects how your body processes a common antiplatelet drug, so your doctors can pick the safest and most effective medicine for you.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are at least 18 years old
- You had a stroke or mini-stroke and can start dual antiplatelet therapy safely
- You arrived at the hospital within 24 hours of your symptoms starting, or within 24 to 96 hours if you are already on or will start dual antiplatelet therapy
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether choosing a blood thinner based on your DNA can prevent more heart problems. If you've had a complex heart procedure, you may be able to get a medication that works best for your body.
This trial looks at whether using clopidogrel by itself (without aspirin) works for people after a new drug-eluting stent, based on a blood test of how your body processes the drug. It may help reduce “extra blood-thinning” if you have a certain genetic type that responds well to clopidogrel.
This trial is for people who have had a stroke caused by narrowed arteries in the brain and are scheduled for a stent placement. It looks at whether a blood test can help predict who might have another stroke despite taking common blood thinners.
This trial is testing whether a new blood test can help predict how well Plavix (clopidogrel) works in people who have had a mild stroke or a high-risk mini-stroke (TIA). If the test works, doctors may be able to adjust treatment sooner to prevent another stroke.
This trial tests a combination of two blood thinners (antiplatelet drugs) to see if they work better than one in people who had a mild stroke caused by a narrowed artery in the brain. If you had a recent first stroke and are otherwise healthy, you may be able to join.
This trial tests whether a quick genetic test can help choose the right antiplatelet medicine for people who have had a mild stroke or a high-risk mini-stroke (TIA). The goal is to see if this personalized approach is possible in a hospital setting.
Hear when a new Ischemic Stroke trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.